NMRA
Price:
$0.6794
Market Cap:
$109.89M
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includ...[Read more]
Industry
Biotechnology
IPO Date
2023-09-15
Stock Exchange
NASDAQ
Ticker
NMRA
According to Neumora Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current PE Ratio is -0.44. This represents a change of -91.94% compared to the average of -5.46 of the last 4 quarters.
The mean historical PE Ratio of Neumora Therapeutics, Inc. Common Stock over the last ten years is -12.09. The current -0.44 PE Ratio has changed 263.89% with respect to the historical average. Over the past ten years (40 quarters), NMRA's PE Ratio was at its highest in in the March 2025 quarter at -0.59. The PE Ratio was at its lowest in in the March 2021 quarter at -40.34.
Average
-12.09
Median
-10.94
Minimum
-24.87
Maximum
0
Discovering the peaks and valleys of Neumora Therapeutics, Inc. Common Stock PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 81.29%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -24.87
Year | PE Ratio | Change |
---|---|---|
2024 | -6.93 | -39.63% |
2023 | -11.48 | -39.15% |
2022 | -18.86 | 81.29% |
2021 | -10.40 | -58.17% |
2020 | -24.87 | -Infinity% |
The current PE Ratio of Neumora Therapeutics, Inc. Common Stock (NMRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-12.42
5-year avg
-14.51
10-year avg
-12.09
Neumora Therapeutics, Inc. Common Stock’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neumora Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Neumora Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Neumora Therapeutics, Inc. Common Stock's PE Ratio?
How is the PE Ratio calculated for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the highest PE Ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the 3-year average PE Ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the 5-year average PE Ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)?
How does the current PE Ratio for Neumora Therapeutics, Inc. Common Stock (NMRA) compare to its historical average?